Objectives: This study was conducted to determine why heart teams recommended transcatheter aortic valve replacement (TAVR) versus surgical AVR (SAVR) for patients at low predicted risk of mortality (PROM) and describe outcomes of these cases.
Background: Historically, referral to TAVR was based predominately on the Society of Thoracic Surgeons (STS) risk model's PROM >3%. In selected cases, heart teams had latitude to overrule these scores. The clinical reasons and outcomes for these cases are unclear.
Methods: Retrospective data were gathered for all TAVR and SAVR cases conducted by 9 hospitals between 2013 and 2017.
Results: Cases included TAVR patients with STS PROM >3% ( = 2,711) and ≤3% ( = 415) and SAVR with STS PROM ≤3% ( = 1,438). Leading reasons for recommending TAVR in the PROM ≤3% group were frailty (57%), hostile chest (22%), severe lung disease (16%), and morbid obesity (13%), and 44% of cases had multiple reasons. Most postoperative and 30-day outcomes were similar between TAVR groups, but the STS PROM ≤3% group had a one-day shorter length of stay (2.5 ± 3.4 vs. 3.5 ± 4.7 days; ≤ 0.001) and higher one-year survival (91.6% vs. 86.0%, =0.002). In patients with STS PROM ≤3%, 30-day mortality was higher for TAVR versus SAVR (2.0% vs. 0.6%; < 0.001).
Conclusions: Heart teams recommended TAVR in patients with STS PROM ≤3% primarily due to frailty, hostile chest, severe lung disease, and/or morbid obesity. Similar postoperative outcomes between these patients and those with STS PROM >3% suggest that decisions to overrule STS PROM ≤3% were merited and may have reduced SAVR 30-day mortality rate.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9252751 | PMC |
| http://dx.doi.org/10.1155/2022/9926423 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Three-Year Outcomes With a Supra-Annular, Self-Expanding Bioprosthesis and a Pericardial Wrap-The FORWARD PRO Study.
Catheter Cardiovasc Interv
December 2024
Center of Innovative Interventions in Cardiology, University Hospital Bonn, Bonn, Germany.
Background: The self-expanding, supra-annular Evolut valve is an established platform for Transcatheter Aortic Valve Implantation (TAVI). Evolut PRO introduced an outer sealing wrap to mitigate paravalvular leakage. We evaluated the 3-year clinical outcomes and valve performance of the Evolut PRO in standard clinical practice for severe aortic stenosis (AS) patients at intermediate or higher risk for surgery.
View Article and Find Full Text PDF4-Dimensional Cardiac Modelling of Multi-phase Computed Tomography for Predicting Outcomes Following Transcatheter Aortic Valve Replacement.
Can J Cardiol
December 2024
Stephenson Cardiac Imaging Centre, Calgary, Alberta, Canada; Libin Cardiovascular Institute, University of Calgary, Calgary, Alberta, Canada; Department of Cardiac Science, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada. Electronic address:
Background: Multi-phase Computed Tomography Angiography (mpCTA) is routinely performed prior to transcatheter aortic valve replacement (TAVR) to determine eligibility and enable pre-procedural planning. Incremental prognostic value may be realized from full-cycle, multi-phase reconstructions to assess the contractile health of cardiac chambers. This study aimed to assess the feasibility of 4D chamber modelling of the left ventricle (LV) to support 3D minimum principal strain (3DminPS) based predictions of clinical outcomes following TAVR.
View Article and Find Full Text PDFThe transaxillary concept for minimally invasive isolated aortic valve replacement: results of 1000 consecutive patients.
Eur J Cardiothorac Surg
November 2024
Center for Minimally Invasive Cardiac Surgery, University Heart Center Dresden, Dresden, Germany.
Article Synopsis
- * The use of this approach significantly increased from 18.7% in 2019 to 97.8% by 2023, with a mean procedure time of 127 minutes and no intraoperative deaths reported.
- * Thirty-day adverse events included a 1.9% rate of major complications, with factors like intraoperative conversion and respiratory failure being linked to higher risks of complications and mortality.
TAVI with the ACURATE neo2 in severe bicuspid aortic valve stenosis: the Neo2 BAV Registry.
EuroIntervention
November 2024
Galway University Hospital, Galway, Ireland.
Background: The ACURATE neo2 is a contemporary transcatheter aortic valve implantation (TAVI) system approved for the treatment of severe aortic stenosis in Europe. The ACURATE neo2 has not been evaluated in bicuspid aortic valve (BAV) stenosis.
Aims: We sought to evaluate the safety and efficacy of ACURATE neo2 in patients with BAV stenosis.
Assessing the impact of socioeconomic distress on hospital readmissions after cardiac surgery.
JTCVS Open
October 2024
Division of Cardiothoracic Surgery, Department of Surgery, University of Virginia, Charlottesville, Va.
Background: The impact of socioeconomic distress on readmission rates following cardiac surgery has not been studied. We hypothesized that patients living in distressed communities would have a higher 30-day readmission rate after cardiac surgery compared to those living in less distressed communities.
Methods: Patients undergoing isolated coronary artery bypass grafting (CABG) between 2016 and 2023 within a regional collaborative were identified.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!